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Abstract 30 
Cases: In addition to previously published case reports, further cases of intravascular migration of 31 
contraceptive implants have been identified from an information request to two national adverse 32 
reaction spontaneous reporting systems. We report on two new cases of insertion into the venous 33 
system with subsequent embolism to a pulmonary artery. Conclusion: Incorporating barium sulfate 34 
into the implant has facilitated diagnosis of these very rare adverse events with the initial diagnosis 35 
of embolism to the pulmonary arterial tree made by chest X-ray. Removal of an implant from a 36 
segmental branch of a pulmonary artery is technically challenging and not without risks. 37 
Unsuccessful removal appears to be preceded by a delay in diagnosis leading to endothelialisation of 38 
the implant in the pulmonary arterial wall. Implications: Subdermal placement of contraceptive 39 
implants over the anterior surface of the biceps rather than in the sulcus between the biceps and 40 
triceps may negate this rare but reported risk. 41 
 42 
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1.  Introduction 47 
The single-rod etonogestrel implant Implanon was available in the UK between 1999 and 2010. We 48 
were aware over this eleven-year period that implants occasionally ‘go missing’ in the body and 49 
cannot be localised[1]. Positive etonogestrel (ENG) blood tests confirmed the presence of the 50 
implant but these non-radiopaque implants were difficult to demonstrate using imaging techniques. 51 
We could not confirm our suspicions that these implants were located in the lung [2]. However, we 52 
felt inadvertent insertion of an implant intravascularly and transit in the venous system to the 53 
pulmonary arterial system was possible.  One of the authors (DM) has seen two patients in which 54 
the key features in the clinical history included painful implant insertion over the area of the sulcus 55 
between the biceps and triceps, the site previously recommended by the manufacturers. In both 56 
cases there was associated extensive bruising over the upper arm with the distal end of the implant 57 
being easy to feel initially and then becoming impalpable. High frequency ultrasound scanning and 58 
magnetic resonance imaging of the arm, chest X-rays and computerised tomography scans failed to 59 
locate the implants.  60 
3 
 
The advent of a modified radiopaque implant and applicator (proprietary name Nexplanon in some 61 
countries and Implanon NXT in others) in 2010[3] makes the imaging and evaluation of these ‘lost 62 
implants’ easier. 63 
Individual case reports of suspected adverse reactions which are sent to regulators spontaneously by 64 
health professionals, pharmaceutical companies and users of medicines themselves are used to 65 
detect ‘signals’ and generate hypotheses of a possible link between a medicine and an adverse 66 
effect[4]. The UK’s Yellow Card Scheme is an example of such a spontaneous reporting system 67 
(https://yellowcard.mhra.gov.uk/). Data derived from Yellow Cards are publicly available for each 68 
drug in the form of Drug Analysis Prints (www.mhra.gov.uk/drug-analysis-prints/). It is important to 69 
note that the inclusion of a reported reaction in a Drug Analysis Print does not necessarily mean it 70 
has been caused by the drug or its delivery vehicle, only that the reporter had a suspicion it may 71 
have. The fact that symptoms occur after use of a drug, and are reported via the Yellow Card 72 
Scheme, does not in itself mean that they are proven to have been caused by the drug/vehicle. The 73 
Drug Analysis Prints for etonogestrel implants show 23 reported cases of pulmonary embolism. An 74 
additional category of ‘device embolisation’ was added in 2014; the tally for device embolisation 75 
currently stands at 1 (period ended 4 April 2016). 76 
 77 
2.  Enquiry to the British and Irish drug regulators 78 
Author involvement with the published cases (MW, SR) in both the UK and the Republic of Ireland 79 
(Cases 1 – 5, Table 1) led us to wonder whether there were any further cases in these two countries. 80 
We asked the UK Medicines & Healthcare products Regulatory Agency (MHRA) about spontaneous 81 
reports of such cases through the UK Yellow Card Scheme. We also asked the Irish Health Products 82 
Regulatory Authority (HPRA) about any cases reported to their national database of suspected 83 
adverse reactions. 84 
 85 
3. Cases identified 86 
Four cases of etonogestrel implant migration to other sites of the body were reported to the UK 87 
MHRA between 2010 and 2016, including Case 1 of the published cases. One of these four cases 88 
could not be confirmed to be in the lung by the reporter; the implant appeared to be in the chest 89 
wall. There is, thus, a total of two UK cases not previously in the public domain (Cases A and B, Table 90 
1). The implants involved in both cases were Nexplanon. Information about the cases is anonymised 91 
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and limited due to the need for confidentiality to protect individuals’ identities. For example we 92 
were not permitted access to the women’s ages. Also some reports to the regulator contain sparser 93 
information. 94 
A single case was known to the Irish HPRA and this was confirmed to have already been the subject 95 
of a published case report (Case 3, Table 1). 96 
 97 
4. Discussion 98 
There is one case in the literature in which an implant was reported to have been inserted into the 99 
peripheral arterial system[5]. This involved the brachial artery and was associated with profuse 100 
bleeding. Thrombus formed in the artery which became occluded. Normal arterial circulation was 101 
restored after vascular surgery. 102 
 103 
All other published case reports are about inadvertent insertion of implants into the venous system. 104 
This is very rare with five cases published over the last two years (Cases 1 – 5, Table 1). These five 105 
case reports from three adjacent countries in Western Europe[6-10] have been written by 106 
radiologists, thoracic surgeons and emergency medicine specialists. All five reports relate to the 107 
radiopaque version of the etonogestrel implant. There is emphasis on the subtleties of various forms 108 
of imaging but little clinical detail. However, the cases are remarkably similar in their clinical 109 
presentation and findings. In all five, the implant was not palpable in the arm and the rod showed 110 
clearly on a chest X-ray. 111 
 112 
A major limitation of this case report is the limited information that the MHRA was able to release to 113 
us about the two further cases that were reported to them; this was due to strict internal rules 114 
about information exchange designed to protect patient and reporter confidentiality.  115 
Heudes et al explained[9] the intravascular journey of the implant as it travels through veins in the 116 
upper arm (from the basilic vein to the axillary vein which becomes the subclavian vein) into the 117 
superior vena cava, right atrium, through the tricuspid valve into the right ventricle and thence into 118 
the pulmonary trunk. The rod is then carried into either the left or right pulmonary artery and along 119 
their successive segmental branches until it finally lodges as an embolus in an arterial branch with a 120 
diameter similar to the 2mm wide rod. The left lower lobe is a favoured site in the lung.  121 
In three out of five cases the women experienced chest pain. Case 3 was associated with a 122 
pneumothorax. Four of the cases had positive etonogestrel levels. Case 4 had haematoma formation 123 
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at the insertion site in the arm immediately after the insertion. Case 5 was on steroids for an auto-124 
immune condition. No lung infarction or arterial thrombosis was reported. 125 
When facing this complication, women react differently. Case 1 did not contemplate any 126 
intervention initially. Others immediately decided to undergo interventional radiological procedures 127 
where a wire and snare was introduced into the pulmonary artery via an accessible vessel in the 128 
groin or neck. This may be unsuccessful, as in the case described by O’Brien et al[8], where the rod 129 
had become endothelialised in the arterial wall and removal risked arterial rupture. In France 130 
thoracoscopy has been a successful mode of removal. Case 3 was offered such a procedure but 131 
declined. Women may feel that open thoracotomy, if offered, would be a step too far in terms of 132 
invasiveness. 133 
We advise that when a radiopaque contraceptive implant cannot be located in either arm by usual 134 
imaging techniques, a chest X-ray should be considered. One of the authors (MW) facilitated the 135 
diagnosis in Case 1 by recommending a chest X-ray and both of the other UK cases were reported 136 
through the Yellow Card Scheme following location by chest X-ray. Clinicians need to ‘think the 137 
unthinkable’ in these cases. 138 
When contraceptive implants are inserted intravascularly women face the real possibility of 139 
persistent side-effects, commonly irregular vaginal bleeding and the theoretical possibility of 140 
pulmonary arterial thrombosis and infection. Younger women may potentially be rendered 141 
involuntarily infertile. ENG blood levels above 90 pg/mL inhibit ovulation. A US study showed median 142 
blood levels of 177 pg/mL (range 68 – 471 pg/mL) at four years compared to 189 pg/mL (range 64 – 143 
803 pg/mL) at three years[11]. We calculate that there would be continued release of ENG from the 144 
implant for at least six years if 30 mcg is the average release rate each day.[12]. However, nothing is 145 
known about the release characteristics when an implant is located intravascularly rather than its 146 
usual subdermal position.  In such women artificial reproductive technology may enable ovulation 147 
and fertilisation but the endometrium is unlikely to respond favourably to exogenous hormone. 148 
We know little about the length of time to diagnosis of intravascular implant embolism in these 149 
cases. There may have been a delay, with health care professionals concentrating on imaging the 150 
arm to find the implant and then seeking help from tertiary level specialists. Women may then need 151 
time to consider whether they undergo a major procedure. The implant in Case 3 had been present 152 
for two years and endothelialisation in the artery may have complicated its removal [8]. Case 1 153 
presented seven months after insertion and Case 5 ten months after insertion; the latter was 154 
removed successfully. 155 
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We know nothing about predisposing factors in these cases. Intuitively this complication would seem 156 
more likely to occur when implants are fitted in the sulcus between the biceps and triceps and there 157 
is little subcutaneous tissue such as in very thin women.  158 
We know nothing about the qualifications or training of the operators who inserted these implants. 159 
All we know is that the operator in Case 5 was a general practitioner. It should be noted that the 160 
Summary of Product Characteristics (SmPC) recommends that healthcare professionals in Europe 161 
have completed training for the use of the etonogestrel implant applicator prior to insertion and 162 
removal of the implant. 163 
In light of the 2015 Montgomery case in the UK Supreme Court[13], patients need to be told about 164 
risks of a procedure even if the risk is very small. A material risk is defined as that which a reasonably 165 
prudent patient thinks is significant. UK law now demands a standard of consent broadly similar to 166 
that required by the professional guidance of the UK General Medical Council and more in line with 167 
many other jurisdictions. 168 
When inserting a contraceptive implant the neurovascular bundle lying beneath the sulcus between 169 
the biceps and triceps should be avoided[14]. Subdermal placement of contraceptive implants over 170 
the anterior surface of the biceps may reduce the risk of intravascular insertion into the basilic vein 171 
or other veins in the vicinity. This was suggested by more than one authority ten years ago[15;16].  172 
Tenting the skin is also imperative; the modified applicator (involved in all seven cases described 173 
here) is not sufficient in itself to set the depth of the implant[17]. Direct visualisation of the tip of the 174 
needle throughout the insertion procedure is necessary, as recommended for avoidance of deep 175 
insertion[17]. Unfortunately, the redesigned applicator restricts the view of the needle [18] 176 
therefore clinicians  are advised to sit or tilt the applicator to ensure subdermal placement.  177 
We recommend that all health care professionals carrying out contraceptive implant insertions and 178 
removals receive approved training. In the UK this is the Letter of Competence in Subdermal 179 
Contraceptive Implant Techniques (Faculty of Sexual & Reproductive Healthcare, www.fsrh.org). 180 
The SmPC and Package Leaflet for Nexplanon/Implanon NXT have been revised in the UK and Ireland 181 
and ‘Dear Health Care Professional’ letters in relation to intravascular insertion were sent out in May 182 
2016. We are pleased that the SmPC wording now mentions avoidance of the sulcus but are not so 183 
content that the SmPC diagram recommends placement over the triceps muscle. Migration to the 184 
pulmonary vasculature is now mentioned. 185 
 186 
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5. Conclusions 189 
We suggest that intravascular migration of implants into the pulmonary vascular tree is not a new 190 
phenomenon. It has come to light because of the addition of barium sulfate to the single-rod 191 
implant product. We surmise that pre-2010 cases of implants in the lung have been missed as the 192 
rods were not radiopaque.  193 
The category of ‘device embolisation’ added to the classification of adverse reaction spontaneous 194 
reports by UK regulators in 2014 is helpful.  195 
Now that there are published case reports in addition to company data about inadvertent 196 
intravascular insertion of contraceptive implants, clinicians must mention this as a very rare 197 
complication in order for consent to be valid. Although a serious adverse event, intravascular 198 
insertion is estimated by MSD to occur in only 1.3 cases per million radiopaque implants sold. 199 
A chest X-ray should be considered in all cases of impalpable implants not located by high frequency 200 
ultrasound where ENG assays are positive. Women found to have an implant in the pulmonary 201 
arterial tree need referral to a thoracic surgeon who will liaise with their interventional radiology 202 
colleagues over proposals for the best removal technique. We believe that early diagnosis is 203 
desirable not only to resolve the uncertainty of the implant’s location but to help prevent 204 
endothelialisation of the implant in the pulmonary artery complicating the implant’s removal. When 205 
an implant cannot be removed women face at least six years of progestogen release from the rod. 206 
Implants should be sited at least 1 cm anterior to the sulcus between the biceps and the triceps. 207 
Subdermal placement needs emphasising, with clinicians making every effort to tent the skin at the 208 
time of implant insertion with the newer applicator, as they did with the previous version. Direct 209 
visualisation of the needle is needed throughout the insertion procedure.  210 
 211 
 212 
 213 
 214 
 215 
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 273 
 274 
Table 1      Summary information about published cases and cases reported to the regulator of 275 
insertion of contraceptive implants into the venous system and intravascular migration to the 276 
pulmonary tree 277 
 278 
Case Country Publication/ report 
to regulator 
Age of woman 
at diagnosis 
Location Outcome 
1 UK Patel et al 2014[6] 36 Left lower 
lobe 
Woman declined any 
intervention* 
2 France D’Journo et al 
2015[7] 
20 Left lower 
lobe 
Segmentectomy via video-
assisted thoracoscopy 
3 Ireland O’Brien et al 2015[8] 23 Left lower 
lobe 
Failed removal attempt by 
interventional radiology 
4 France Heudes et al 2015[9] 18 Right upper 
lobe 
Successful removal by 
interventional radiology 
5 France Maroteix et al 
2015[10] 
27 Left lower 
lobe 
Successful removal by 
interventional radiology 
A UK Spontaneous report 
2013  
NK NK Failed interventional 
radiological attempt at 
removal 
B UK Spontaneous report 
2016  
NK NK NK 
 279 
*As a result of author involvement with this case (MW), we know that this woman subsequently 280 
underwent an interventional radiological procedure 12 months after insertion which was 281 
unsuccessful. 282 
NK = not known 283 
 284 
